Sergios Tsakatikas

Mr. Sergios Tsakatikas

Metaxa Cancer Hospital
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Christo KOLEChristo KOLE
Christo KOLE
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
STSergios Tsakatikas
Sergios Tsakatikas
MVMichail Vailas
Michail Vailas
Dimitrios MorisDimitrios Moris
Dimitrios Moris
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Hepatocellular carcinoma (HCC) is one of one of the most frequent liver cancers and the fourth leading cause of cancer-related mortality worldwide. Current treatment options such as surgery, neoadjuvant chemoradiotherapy, liver transplantation, and radiofrequency ablation will benefit only a very small percentage of patients. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The aim of our study is to present the currently ongoing clinical trials and to evaluate the efficacy of immunotherapy in HCC. In this paper, we demonstrate that combination of different immunotherapies or immunotherapy with other modalities results in better overall survival (OS) and progression-free survival (PFS) compared to single immunotherapy agent. Another objective of this paper is to demonstrate and highlight the importance of tumor microenvironment as a predictive and prognostic marker and its clinical implications in immunotherapy response.

17 November 2021 in Immunotherapy
Verified
Journal Article
Closed access
Christo KOLEChristo KOLE
Christo KOLE
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
STSergios Tsakatikas
Sergios Tsakatikas
NKNikolaos-Iasonas Kouris
Nikolaos-Iasonas Kouris
GPGeorge Papaxoinis
George Papaxoinis
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority of patients with gastric cancer are...

30 June 2021 in Immunotherapy
Verified
Journal Article
Closed access
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
GPGeorgios Papageorgiou
Georgios Papageorgiou
STSergios Tsakatikas
Sergios Tsakatikas
RFRodanthi Fioretzaki
Rodanthi Fioretzaki
Christo KOLEChristo KOLE
Christo KOLE
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Cholangiocarcinoma (CCA) is a rare malignancy with generally dismal prognosis. Immunotherapy has revolutionized the management of cancer patients during the last decade, offering durable responses ...

1 September 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
Christo KOLEChristo KOLE
Christo KOLE
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
MVMichail Vailas
Michail Vailas
Maria ToliaMaria Tolia
Maria Tolia
MSMaria Sotiropoulou
Maria Sotiropoulou
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS

20 November 2020 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
GPGeorgios Papageorgiou
Georgios Papageorgiou
STSergios Tsakatikas
Sergios Tsakatikas
RFRodanthi Fioretzaki
Rodanthi Fioretzaki
CKChristos Kosmas
Christos Kosmas
Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis. Current treatment modalities only offer modest activity and usually of short duration, so there is an urgent need for the conduct of clinical trials exploring new treatment options and modalities. The vincristine-irinotecan-temozolomide and bevacizumab (VITb) regimen is an option of special interest, as it has produced encouraging results in young patients with various relapsed/refractory childhood and adolescence solid tumors, with an acceptable toxicity profile. With the current report, we present the case of a young male patient who was treated for GBM in second relapse at out institution, after previous surgical attempts and two radiotherapy sessions in conjunction with temozolomide and experienced a major and long-lasting response, weaned off steroids, to the VITb regimen followed by bevacizumab maintenance. The above case is discussed in the context of the existing literature regarding available evidence of synergy between the drugs used and the activity of certain components of the combination (i.e. combination of temozolomide-irinotecan ± vincristine, or bevacizumab-irinotecan in GBM) or the complete VITb regimen in other pediatric/adolescence solid tumors and the few cases reported with GBM.